Xenogeneic Heart Transplantation

Indication / Application

Validation of donor gene-editing efficacy, preclinical screening of novel targeted immunosuppressants (e.g., co-stimulation blockade, anti-CD40/CD40L mAbs), evaluation of systemic biocompatibility, and mechanism studies on xenograft vasculopathy and consumptive coagulopathy.

Modeling Method

1. Donor Organ Preservation: Standardized cold harvesting of the donor heart from genetically modified swine, utilizing advanced, nutrient-rich cardioplegic solutions to minimize ischemic-reperfusion injury (IRI).

2. Surgical Transplantation:

• • Heterotopic Platform: Ectopic vascular anastomosis in the recipient’s abdominal or cervical cavity to establish a beating, non-working graft model for long-term immunological and biopsy tracking.

  • Orthotopic Platform: Conducted under full cardiopulmonary bypass (CPB) support. Complete native cardiectomy is performed, followed by anatomical implantation of the porcine graft to fully support systemic circulation.

3. Perioperative Management: Deployment of specialized post-transplant induction and maintenance immunotherapy combined with 24/7 high-tier intensive care unit (ICU) monitoring.

Clinical Relevance

• Translational & Physiological Homology: Genetically modified porcine hearts closely replicate human cardiac geometry and hemodynamic workload. The pig-to-NHP model is the mandatory global regulatory benchmark required to demonstrate safety before transitioning to clinical trials.

• Immunological Fidelity: NHPs present the critical immunological barrier (including pre-existing natural antibodies) needed to evaluate human-like rejection profiles. Execution within our AAALAC-accredited, OECD GLP-compliant infrastructure provides high-fidelity, submission-ready data for global regulatory bodies (FDA, EMA, NMPA).

Key Evaluation Endpoints

In Vivo / Surgical / Imaging

• Graft Functionality: Continuous telemetric or hardwired ECG monitoring for rhythm stability; serial Transthoracic/Transesophageal Echocardiography (ECHO) evaluating ejection fraction (EF), fractional shortening (FS), and myocardial contractility.

• Hemodynamics & Perfusion: Real-time arterial, central venous, and pulmonary pressure tracking alongside cardiac output (CO) metrics.

• Biopsy Monitoring: Serial ultrasound-guided fine-needle or endomyocardial biopsies for real-time intra-graft structural evaluation.

Histopathology (Gold Standard)

• Rejection Grading: H&E, Masson's Trichrome, and VVG staining scored strictly against the updated ISHLT (International Society for Heart and Lung Transplantation) and xenotransplantation consensus scales to grade cellular and antibody-mediated rejection.

• Immunohistochemistry (IHC/IF):

• Complement Activation: C4d, C3d, and C5b-9 deposition profiling.

• Thrombosis & Infiltration: Endothelial/platelet evaluation (CD31, CD61) and leukocyte profiling (CD3, CD20, CD68).

Hematology & Molecular Biology

• Coagulation Kinetics: Full automated profiling of D-dimer, fibrinogen, PT/aPTT, and Thromboelastography (TEG) to monitor for thrombotic microangiopathy (TMA) or consumptive coagulopathy.

• Humoral Immunoprofiling: Flow cytometry cross-matching and ELISA tracking of induced anti-porcine antibody titers (IgG/IgM).

• Inflammatory Cascade: Multiplex cytokine profiling (TNF-alpha, IL-6, IL-1beta) via RT-qPCR or Western Blot.